SYSTEMATIC LITERATURE REVIEW ON MULTI-INDICATION PRICING MODELS IN ONCOLOGICAL DRUGS

被引：2
|
作者：
Manganelli, A. [1 ]
Badia, X. [2 ]
Gonzalez, P. [3 ]
机构：
[1] CRES UPF, Barcelona, Spain
[2] Omakase Consulting, Barcelona, Spain
[3] Bristol Myers Squibb, Madrid, Spain
来源：
VALUE IN HEALTH | 2017年 / 20卷 / 09期
关键词：
D O I：
10.1016/j.jval.2017.08.391
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
PCN308
引用
收藏
页码：A467 / A467
页数：1
相关论文
共 50 条
  • [1] Price Models for Multi-indication Drugs: A Systematic Review
    Carlos Campillo-Artero
    Jaume Puig-Junoy
    José Luis Segú-Tolsa
    Marta Trapero-Bertran
    [J]. Applied Health Economics and Health Policy, 2020, 18 : 47 - 56
  • [2] Price Models for Multi-indication Drugs: A Systematic Review
    Campillo-Artero, Carlos
    Puig-Junoy, Jaume
    Segu-Tolsa, Jose Luis
    Trapero-Bertran, Marta
    [J]. APPLIED HEALTH ECONOMICS AND HEALTH POLICY, 2020, 18 (01) : 47 - 56
  • [3] Indication-Based Pricing for Multi-Indication Drugs
    Adida, Elodie
    [J]. MANAGEMENT SCIENCE, 2023, 70 (11) : 7506 - 7523
  • [4] FEASIBILITY OF MULTI-INDICATION PRICING: A TARGETED REVIEW OF THE INTERNATIONAL LITERATURE
    Turner, A.
    Syed, I. A.
    Hancock-Howard, R.
    [J]. VALUE IN HEALTH, 2019, 22 : S306 - S306
  • [5] PAYER PERSPECTIVES ON PRICING OF MULTI-INDICATION PRODUCTS
    Mills, M.
    Miracolo, A.
    Michaeli, D.
    Kanavos, P.
    [J]. VALUE IN HEALTH, 2020, 23 : S655 - S655
  • [6] Patient Welfare Implications of Indication-Specific Value-Based Pricing of Multi-Indication Drugs
    Jiang, Yawen
    Li, Meng
    Jiang, Shan
    Si, Lei
    Gu, Yuanyuan
    [J]. VALUE IN HEALTH, 2024, 27 (03) : 273 - 277
  • [7] HOW TO INTRODUCE MULTI-INDICATION BASED PRICING IN FINLAND?
    Karppinen, M. L.
    Ihalmo, P.
    Hjortsberg, C.
    [J]. VALUE IN HEALTH, 2018, 21 : S82 - S83
  • [8] ARE PHARMACEUTICAL COMPANIES PRIORITIZING MULTI-INDICATION DRUGS?
    Lurie, B. F.
    Rubinstein, J.
    Rubinstein, E. R.
    Rosenblum, S. B.
    Ho, Y.
    [J]. VALUE IN HEALTH, 2017, 20 (09) : A900 - A900
  • [9] Multi-Indication Pricing: Nice in Theory but Can it Work in Practice?
    Mestre-Ferrandiz, Jorge
    Zozaya, Neboa
    Alcala, Bleric
    Hidalgo-Vega, Alvaro
    [J]. PHARMACOECONOMICS, 2018, 36 (12) : 1407 - 1420
  • [10] Multi-Indication Pricing: Nice in Theory but Can it Work in Practice?
    Jorge Mestre-Ferrandiz
    Néboa Zozaya
    Bleric Alcalá
    Álvaro Hidalgo-Vega
    [J]. PharmacoEconomics, 2018, 36 : 1407 - 1420
12345